CoChat

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males

Open access
Sargentini‐Maier, Maria Laura, Rolan, Paul, Connell, John, Tytgat, Dominique, Jacobs, Tom, Pigeolet, Etienne, Riethuisen, Jean‐Michel, Stockis, Armel · 2007 · British Journal of Clinical Pharmacology
Cited by 141

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

What is already known about this subject • Brivaracetam is a new chemical entity structurally related to levetiracetam, displaying a markedly higher affinity for the binding site believed to be primarily involved in the antiepileptic effect of levetiracetam. • Studies to evaluate the pharmacological profile of brivaracetam demonstrate an approximately 10‐fold higher potency than levetiracetam as well as a higher efficacy in models of epilepsy. • If translated into therapeutic effects in humans, this would mean a greater decrease in seizure frequency and a higher number of responders and seizure‐free patients in refractory epileptic patients as seen with levetiracetam. What this study adds • This article reports the results of the first in human study with brivaracetam. Its pharmacokinetics and adverse events profile after single administration are evaluated, together with the effect of food on the former. Aims: The objective of the study was to evaluate the pharmacokinetics (and how they are affected by food), CNS pharmacodynamics and the adverse event profile of brivaracetam after single increasing doses. Methods: Healthy males (n = 27, divided into three alternating panels of nine subjects) received two different single oral doses of brivaracetam (10–1400 mg) and one dose of placebo during three periods of a randomized, double‐blind, placebo‐controlled study. The effect of food on its pharmacokinetics was assessed using a standard two‐way crossover design in a further eight subjects who received two single oral doses of brivaracetam (150 mg) in the fasting state and after a high fat meal. Results: Adverse events, none of which were serious, were mostly CNS‐related and included somnolence, dizziness, and decreased attention, alertness, and motor control. Their incidence, severity and duration were dose‐related. The maximum tolerated dose was established to be 1000 mg. Severe somnolence lasting 1 day occurred in one subject following 1400 mg. Brivaracetam was rapidly absorbed under fasting conditions, with a median tmax of approximately 1 h. Cmax was dose‐proportional from 10 to1400 mg, whereas AUC deviated from dose linearity above 600 mg. A high‐fat meal had no effect on AUC (point estimate 0.99, 90%CI: 0.92–1.07) but delayed tmax (3 h) and decreased Cmax (point estimate 0.72, 90%CI: 0.66–0.79). Conclusions: Brivaracetam was well tolerated after increasing single doses that represent up to several times the expected therapeutic dose. Brivaracetam was found to have desirable pharmacokinetic properties. The most common adverse events were somnolence and dizziness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2006.02829.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 141

Metadata

Authors
Sargentini‐Maier, M. L., Rolan, P., Connell, J., Tytgat, D., Jacobs, T., Pigeolet, E., Riethuisen, J., & Stockis, A.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2007-01-12
Volume
63
Issue
6
Pages
680-688
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2037616672
Cited by
141
References
2
FWCI
4.37
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.